6 results about "Ventricular conduction" patented technology

The invention relates to a programming device for programming an implantable medical device for stimulating a human or animal heart. In operation, the following steps are performed: a) allowing selection of one of at least two electrode lead configurations of the implantable medical device (1) for stimulating the human or animal heart (7), wherein the at least two electrode lead configurations comprise a second electrode lead configuration, wherein at least one electrode lead (4) of the implantable medical device (1) is connected to an electrode lead port (3) of the implantable medical device (1), the electrode lead port (3) being configured to receive an electrode lead (4) for stimulating a second heart region or for detecting electrical signals at the second heart region, wherein the second heart region is part of a ventricular conduction system of the heart (7), wherein the at least one electrode lead (4) is implanted or is intended to be implanted in the second heart region; b) generating and releasing a notification signal if the second electrode lead configuration is selected.

Methods and systems are provided for a rate adaptive bi-ventricular fusion pacing. The methods and systems deliver a first pulse at a left ventricular (LV) lead and a second pulse at a right ventricular (RV) lead based on a paced atrio-ventricular (AV) delay. The first pulse timed to be delivered concurrently with an intrinsic ventricular conduction. The methods and systems further repeat the delivery of the first pulse and the second pulse for a predetermined number of cycles. Additionally, the methods and systems measure an intrinsic AV conduction interval, and adjust the paced AV delay based on the intrinsic AV conduction interval and a negative hysteresis delta.

The application belongs to the field of heart disease treatment and natural medicine compound, and provides application of bufalin or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating reperfusion arrhythmia. Experiments in vitro and in vivo prove that bufalin inhibits L-type calcium channels in a concentration-dependent manner, reduces extracellular calcium ion inflow, and further reduces the incidence of ventricular arrhythmia, arrhythmia, reduces ventricular conduction time, increases left ventricular conduction velocity, and reduces ventricular conduction dispersion; and provides a new drug selection for the treatment of reperfusion arrhythmia.

A medical device is configured to sense at least one cardiac electrical signal and generate pacing pulses according to a first pacing therapy by generating pacing pulses for delivery to a first combination of ventricular pacing sites including at least one ventricular conduction system pacing site. The medical device may be configured to determine a ventricular conduction condition based on a QRS signal feature of the sensed cardiac signal during the first pacing therapy. The medical device may change to a second pacing therapy different than the first pacing therapy based on the determined ventricular conduction condition.

Systems and methods for dynamically controlling His-bundle pacing (HBP) according to an indication of a rate-related or intermittent atrioventricular (AV) block in a subject are disclosed. An exemplary medical system includes an AV conduction monitor to detect an indication of either a presence or an absence of intermittent or rate-related AV conduction disturbance using physiologic information of the subject. In the event that an intermittent or rate-related AV conduction disturbance is present, a control circuit provides a control signal to an electrostimulation circuit to deliver HBP pulses. If there is no indication of intermittent or rate-related AV conduction disturbance, or a previously detected intermittent or rate-related AV conduction disturbance has been terminated, the control circuit withholds or discontinues delivery of the HBP pulses to promote intrinsic ventricular conduction and activation.

The application belongs to the field of heart disease treatment and natural medicine compound, and provides application of bufalin or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating reperfusion arrhythmia. Experiments in vitro and in vivo prove that bufalin inhibits L-type calcium channels in a concentration-dependent manner, reduces extracellular calcium ion inflow, and further reduces the incidence of ventricular arrhythmia, arrhythmia, reduces ventricular conduction time, increases left ventricular conduction velocity, and reduces ventricular conduction dispersion; and provides a new drug selection for the treatment of reperfusion arrhythmia.